Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBUR trial of exenatide once weekly or sitagliptin added to basal insulin in type 2 diabetes mellitus
2017-004326-15Phase 4Completed
- Sponsor
- Università degli Studi Gabriele d'Annunzio Chieti e Pescara
- Start
- Jun 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Bydureon add-on to basal insulin with sitagliptin add-on to basal insulin (2 arms). Primary endpoint: Change in endothelial microparticle levels. Started Jun 2021; status: completed.
02
Drugs
exenatidesitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-004326-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004326-15.